These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 25337991)

  • 1. Drug strategies targeting CYP51 in neglected tropical diseases.
    Choi JY; Podust LM; Roush WR
    Chem Rev; 2014 Nov; 114(22):11242-71. PubMed ID: 25337991
    [No Abstract]   [Full Text] [Related]  

  • 2. Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development.
    Moraes CB; Giardini MA; Kim H; Franco CH; Araujo-Junior AM; Schenkman S; Chatelain E; Freitas-Junior LH
    Sci Rep; 2014 Apr; 4():4703. PubMed ID: 24736467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo studies of the antiparasitic activity of sterol 14α-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi.
    Soeiro Mde N; de Souza EM; da Silva CF; Batista Dda G; Batista MM; Pavão BP; Araújo JS; Aiub CA; da Silva PB; Lionel J; Britto C; Kim K; Sulikowski G; Hargrove TY; Waterman MR; Lepesheva GI
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4151-63. PubMed ID: 23774435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitrypanosomal Activity of Sterol 14α-Demethylase (CYP51) Inhibitors VNI and VFV in the Swiss Mouse Models of Chagas Disease Induced by the Trypanosoma cruzi Y Strain.
    Guedes-da-Silva FH; Batista DG; Da Silva CF; De Araújo JS; Pavão BP; Simões-Silva MR; Batista MM; Demarque KC; Moreira OC; Britto C; Lepesheva GI; Soeiro MN
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid Chagas Disease Drug Target Discovery Using Directed Evolution in Drug-Sensitive Yeast.
    Ottilie S; Goldgof GM; Calvet CM; Jennings GK; LaMonte G; Schenken J; Vigil E; Kumar P; McCall LI; Lopes ES; Gunawan F; Yang J; Suzuki Y; Siqueira-Neto JL; McKerrow JH; Amaro RE; Podust LM; Durrant JD; Winzeler EA
    ACS Chem Biol; 2017 Feb; 12(2):422-434. PubMed ID: 27977118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4-Aminopyridyl-based CYP51 inhibitors as anti-Trypanosoma cruzi drug leads with improved pharmacokinetic profile and in vivo potency.
    Calvet CM; Vieira DF; Choi JY; Kellar D; Cameron MD; Siqueira-Neto JL; Gut J; Johnston JB; Lin L; Khan S; McKerrow JH; Roush WR; Podust LM
    J Med Chem; 2014 Aug; 57(16):6989-7005. PubMed ID: 25101801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanding the binding envelope of CYP51 inhibitors targeting Trypanosoma cruzi with 4-aminopyridyl-based sulfonamide derivatives.
    Vieira DF; Choi JY; Roush WR; Podust LM
    Chembiochem; 2014 May; 15(8):1111-20. PubMed ID: 24771705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complexes of Trypanosoma cruzi sterol 14α-demethylase (CYP51) with two pyridine-based drug candidates for Chagas disease: structural basis for pathogen selectivity.
    Hargrove TY; Wawrzak Z; Alexander PW; Chaplin JH; Keenan M; Charman SA; Perez CJ; Waterman MR; Chatelain E; Lepesheva GI
    J Biol Chem; 2013 Nov; 288(44):31602-15. PubMed ID: 24047900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Candidate VT-1161's Antiparasitic Effect In Vitro, Activity in a Murine Model of Chagas Disease, and Structural Characterization in Complex with the Target Enzyme CYP51 from Trypanosoma cruzi.
    Hoekstra WJ; Hargrove TY; Wawrzak Z; da Gama Jaen Batista D; da Silva CF; Nefertiti AS; Rachakonda G; Schotzinger RJ; Villalta F; Soeiro Mde N; Lepesheva GI
    Antimicrob Agents Chemother; 2016 Feb; 60(2):1058-66. PubMed ID: 26643331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in Chagas disease drug development: 2009-2010.
    Buckner FS; Navabi N
    Curr Opin Infect Dis; 2010 Dec; 23(6):609-16. PubMed ID: 20885320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51.
    Vieira DF; Choi JY; Calvet CM; Siqueira-Neto JL; Johnston JB; Kellar D; Gut J; Cameron MD; McKerrow JH; Roush WR; Podust LM
    J Med Chem; 2014 Dec; 57(23):10162-75. PubMed ID: 25393646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel structural CYP51 mutation in Trypanosoma cruzi associated with multidrug resistance to CYP51 inhibitors and reduced infectivity.
    Franco CH; Warhurst DC; Bhattacharyya T; Au HYA; Le H; Giardini MA; Pascoalino BS; Torrecilhas AC; Romera LMD; Madeira RP; Schenkman S; Freitas-Junior LH; Chatelain E; Miles MA; Moraes CB
    Int J Parasitol Drugs Drug Resist; 2020 Aug; 13():107-120. PubMed ID: 32688218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Trypanosoma cruzi sterol 14α-demethylase (CYP51).
    Lepesheva GI; Villalta F; Waterman MR
    Adv Parasitol; 2011; 75():65-87. PubMed ID: 21820552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection.
    Calvet CM; Choi JY; Thomas D; Suzuki B; Hirata K; Lostracco-Johnson S; de Mesquita LB; Nogueira A; Meuser-Batista M; Silva TA; Siqueira-Neto JL; Roush WR; de Souza Pereira MC; McKerrow JH; Podust LM
    PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006132. PubMed ID: 29281643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural basis for rational design of inhibitors targeting Trypanosoma cruzi sterol 14α-demethylase: two regions of the enzyme molecule potentiate its inhibition.
    Friggeri L; Hargrove TY; Rachakonda G; Williams AD; Wawrzak Z; Di Santo R; De Vita D; Waterman MR; Tortorella S; Villalta F; Lepesheva GI
    J Med Chem; 2014 Aug; 57(15):6704-17. PubMed ID: 25033013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting CYP51 for drug design by the contributions of molecular modeling.
    Rabelo VW; Santos TF; Terra L; Santana MV; Castro HC; Rodrigues CR; Abreu PA
    Fundam Clin Pharmacol; 2017 Feb; 31(1):37-53. PubMed ID: 27487199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sterol 14α-Demethylase Structure-Based Optimization of Drug Candidates for Human Infections with the Protozoan Trypanosomatidae.
    Friggeri L; Hargrove TY; Rachakonda G; Blobaum AL; Fisher P; de Oliveira GM; da Silva CF; Soeiro MNC; Nes WD; Lindsley CW; Villalta F; Guengerich FP; Lepesheva GI
    J Med Chem; 2018 Dec; 61(23):10910-10921. PubMed ID: 30451500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lead optimization generates selenium-containing miconazole CYP51 inhibitors with improved pharmacological profile for the treatment of fungal infections.
    Xu H; Yan ZZ; Guo MB; An R; Wang X; Zhang R; Mou YH; Hou Z; Guo C
    Eur J Med Chem; 2021 Apr; 216():113337. PubMed ID: 33713977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.
    Yates CM; Garvey EP; Shaver SR; Schotzinger RJ; Hoekstra WJ
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3243-3248. PubMed ID: 28651982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hit-to-Lead Optimization of a Novel Class of Potent, Broad-Spectrum Trypanosomacides.
    Russell S; Rahmani R; Jones AJ; Newson HL; Neilde K; Cotillo I; Rahmani Khajouei M; Ferrins L; Qureishi S; Nguyen N; Martinez-Martinez MS; Weaver DF; Kaiser M; Riley J; Thomas J; De Rycker M; Read KD; Flematti GR; Ryan E; Tanghe S; Rodriguez A; Charman SA; Kessler A; Avery VM; Baell JB; Piggott MJ
    J Med Chem; 2016 Nov; 59(21):9686-9720. PubMed ID: 27548560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.